Literature DB >> 2969081

Heparin and heparinoids impair adrenaline and platelet-activating factor but not thrombin-induced inhibition of adenylate cyclase and stimulation of GTP hydrolysis in human platelet membranes.

B Willuweit1, K Aktories.   

Abstract

The effects of heparins and heparinoids were studied on adenylate cyclase and GTPase activities in human platelet membranes. Inhibition of adenylate cyclase by adrenaline and platelet activating factor was completely abolished by heparin at 1 microgram/ml. At similar concentration heparin blocked the stimulation of high affinity GTPase(s) by these hormonal factors. In contrast, heparin (up to 30 micrograms/ml) did not abolish adenylate cyclase inhibition and stimulation of GTP hydrolysis by thrombin in the absence of antithrombin III. In the presence of antithrombin III, thrombin action on adenylate cyclase was blocked by unfractionated and high molecular weight heparin at 0.1 microgram/ml. Low molecular weight heparins and pentosanpolysulfate were less or not effective. In contrast, all high and low molecular weight heparins tested were almost equally potent in inhibiting adrenaline-induced inhibition of adenylate cyclase in the absence of antithrombin III. The data indicate that heparins discriminate platelet activating factor and adrenaline-induced inhibition of adenylate cyclase from the inhibitory action of thrombin and delineate different structural requirements for the interaction of heparins with the adenylate cyclase system and antithrombin III.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2969081     DOI: 10.1007/bf00168850

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  24 in total

1.  Reduction of adenylate cyclase activity in lysates of human platelets by the alpha-adrenergic component of epinephrine.

Authors:  K H Jakobs; W Saur; G Schultz
Journal:  J Cyclic Nucleotide Res       Date:  1976 Nov-Dec

2.  Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets.

Authors:  M D Houslay; D Bojanic; D Gawler; S O'Hagan; A Wilson
Journal:  Biochem J       Date:  1986-08-15       Impact factor: 3.857

3.  The enzymatic preparation of [alpha-(32)P]nucleoside triphosphates, cyclic [32P] AMP, and cyclic [32P] GMP.

Authors:  T F Walseth; R A Johnson
Journal:  Biochim Biophys Acta       Date:  1979-03-28

4.  Heparin inhibits proliferation of fetal vascular smooth muscle cells in the absence of platelet-derived growth factor.

Authors:  W E Benitz; D S Lessler; J D Coulson; M Bernfield
Journal:  J Cell Physiol       Date:  1986-04       Impact factor: 6.384

Review 5.  Human plasma proteinase inhibitors.

Authors:  J Travis; G S Salvesen
Journal:  Annu Rev Biochem       Date:  1983       Impact factor: 23.643

6.  Inhibition of platelet adenylate cyclase by 1-O-alkyl-2-O-acetyl-sn-glyceryl-3-phosphorylcholine (platelet-activating factor).

Authors:  R J Haslam; M Vanderwel
Journal:  J Biol Chem       Date:  1982-06-25       Impact factor: 5.157

7.  Ni-mediated inhibition of human platelet adenylate cyclase by thrombin.

Authors:  K Aktories; K H Jakobs
Journal:  Eur J Biochem       Date:  1984-12-03

8.  Platelet-activating factor stimulates phosphatidylinositol turnover in human platelets.

Authors:  D E MacIntyre; W K Pollock
Journal:  Biochem J       Date:  1983-05-15       Impact factor: 3.857

9.  Removal of the anticoagulant activities of the low molecular weight heparin fractions and fragments with flavobacterial heparinase.

Authors:  V C Yang; H Bernstein; C L Cooney; J C Kadam; R Langer
Journal:  Thromb Res       Date:  1986-12-01       Impact factor: 3.944

10.  Modulation of adenylate cyclase activity by sulfated glycosaminoglycans. II. Effects of mucopolysaccharides and dextran sulfate on the activity of adenylate cyclase derived from various tissues.

Authors:  A Amsterdam; A Reches; Y Amir; Y Mintz; Y Salomon
Journal:  Biochim Biophys Acta       Date:  1978-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.